FDA Advisory Panel Recommends Six Peptides for Compounding Bulks List

The FDA’s Pharmacy Compounding Advisory Committee voted to recommend six peptides, including BPC-157 and TB-500, for the 503A Bulks List, a move that could eventually reopen a legal compounding pipeline for these highly requested therapies. During the July 23-24, 2026 meeting, the panel overrode agency staff scientists who opposed adding any of the peptides, citing critical gaps in clinical evidence. Scientists argued that the available data, including just five small trials for BPC-157, were too brief and limited to prove safety or efficacy.

Despite those objections, the committee voted 8-6 to recommend BPC-157, KPV, and TB-500. MOTS-c passed on a 7-5 vote, while Semax and Epitalon were also recommended. Emideltide was the only peptide rejected, failing by a 7-6 vote.

While this is a significant regulatory shift for clinics facing heavy patient demand for peptide-based healing and longevity protocols, it does not grant immediate permission to prescribe. These recommendations are strictly nonbinding. The FDA must formally accept the committee’s guidance and complete the official rulemaking process before these substances can be legally compounded under section 503A. Until then, sourcing or compounding BPC-157 or TB-500 remains a regulatory risk. For now, the most practical approach is to track this rulemaking closely, advise inquiring patients of the transitional regulatory status, and audit your pharmacy partners to ensure you stay aligned with active federal compliance standards.

Source: AJMC, https://www.ajmc.com/view/fda-panel-backs-6-peptides-for-compounding